Sunday, December 22, 2024
Home Blog Page 151

The History of clinical research

0

The evolution of clinical research traverses a long and mesmerizing journey. From the first recorded trial of legumes in biblical times to the first randomized controlled of trial of streptomycin in 1946.

The history of clinical trial covers a wide variety of challenges – scientific, ethical and regulatory. The UK Medical Research Council’s (MRC) trial of patulin for common cold in 1943 was the first double blind controlled trial.

The journey moves from dietary therapy – legumes and lemons – to drugs. These were followed by changes in regulatory and ethics milieu.

562 BC – 1537: Pre-James Lind Era:

605 BC Book of Daniel: The world’s first clinical trial is recorded in the “Book of Daniel” in The Bible.  During rule of King Nebuchadnezzar in Babylon, he ordered his people to eat only meat and drink only wine, while he allowed vegetarians to eat legumes and water — but only for 10 days. When the experiment ended, the vegetarians appeared better nourished than the meat-eaters.  The king endorsed legume lovers to continue their diet.

500 BC The Hippocratic Oath: Hippocrates is called father of medicine and he was a founder of Hippocratic School of Medicine. He established medicine a separate profession and credited with coining Hippocratic Oath. By taking it, physicians and other healthcare professionals affirm to practice medicine justly and ethically.

1537: Ambroise Pare in 1537 was responsible for the treatment of the battlefield wounded soldiers. As there was insufficient amount of oil as needed, He was constrained to apply digestive made of yolks of eggs, oil of roses and turpentine in place of oil for battlefield wounded soldiers. He found those to whom he had applied the digestive medicament feeling but little pain, their wounds neither swollen nor inflamed, and having slept through the night. This is an example of accidently performed comparative trial.

1747: James Lind and Scurvy Trial: He planned a comparative trial of the most promising cure for scurvy. On May 1747, he selected twelve patients in the scurvy. They lay together in one place, he gave diet common to all. The consequence was that the most sudden and visible good effects were alleged from the use of oranges and lemons.

1800: Arrival of Placebo: Hooper’s Medical Dictionary of 1811 defined it as “an epithet given to any medicine more to please than benefit the patient.” However, it was only in 1863 that United States physician Austin Flint planned the first clinical study, he treated 13 patients suffering from rheumatism with an herbal extract which was advised instead of an established remedy. In 1886, Flint described the study in his book A Treatise on the Principles and Practice of Medicines“This was given regularly, and became well known in my wards as the ‘placeboic remedy’ for rheumatism. The favorable progress of the cases was such as to secure for the remedy in general the whole confidence of the patients.

1887 National Institute of Health (NIH) Founded: the National Institute of Health was founded by Joseph J. Kinyoun. Today the NIH is the largest source of funding for medical research in the world, investing $30.9 billion annually to support scientific discovery.

1906 FDA Pure Food and Drug Act: President Theodore Roosevelt signed the FDA Pure Food and Drug Act into law, which regulated that products could not be sold for indications outside the labelling and prohibited interstate transportation of unlawful food and drugs.

1928 Sir Alexander Fleming Discovers Penicillin: Alexander Fleming’s cluttered and untidy

lab yielded one of the most important discoveries in the history of medicine as

Penicillin which was identified on mould growing on a stack of staphylococci cultures. Penicillin was the most efficacious life-saving drugs in the world for the  treatment of bacterial infections.

1932-1972:The Tuskegee Syphilis Study: The US Public Health Service conducted studies on 600 (including 201 control) subjects to study the effects of syphilis. Subjects did not provide informed consent and were denied access to Penicillin, a proven treatment for syphilis.

1937 Elixir Sulfanilamide Disaster: Chief chemist, Harold Cole Watkins, liquefied the drug by dissolving it in the toxic compound diethylene glycol, but failed to test the compound for toxicity since this was not a requirement at the time. Over 100 patients died after consuming Elixir Sulfanilamide.

1938 Federal Food, Drug and Cosmetic Act: Following the Elixir Sulfanilamide disaster, 1938 Federal Food, Drug and Cosmetic Act passed by the U.S. Congress   which required proof of safety before the release of a new drug.

1939-1945 World War II Experiments: Prisoners were subjected to hazardousexperiments with the goal of developingnew weapons, to aid in treating injuredGerman soldiers, and to advance their eugenic racial ideologies.

1943: The First Double blind Controlled Trial – Patulin for Common Cold: The Medical Research Council (MRC) UK carried out a trial in 1943-4 in order to investigate patulin treatment for (an extract of Penicillium patulinum) the common cold. The study was carefully controlled by keeping the physician and the patient blinded to the treatment. The outcome of the trial was unsatisfactory as the analysis of trial data did not show any protective effect of patulin.

1944 Multicenter Studies: For the first time, trials were conducted at different sites using the same protocol, with all the centers’ results assessed together. This finally allowed for larger numbers of participants and a wider range of population groups to be studied, which strengthens research trial designs and analyses.

1944-1974 Human Radiation Experiments: During the War, thousands of U.S. citizens became the innocent and unknowing victims of over 4,000 secret experiments sponsored by the U.S. government with the aim of determining the effects of atomic radiation on the human body, often using doses likely to harm the subjects.

1946 First Randomized Curative Trial –  Randomized Controlled Trial of the Streptomycin:The first randomized control trial of streptomycin in pulmonary tuberculosis was carried out in 1946 by MRC of the UK. Determination of whether a patient would be treated by streptomycin and bed-rest (S case) or by bed-rest alone (C case) was completed by the reference to a statistical series based on random sampling numbers drained up for each sex at each centre by Professor Bradford Hill.

1947 Nuremberg Code: This Code established the requirements for informed consent, absence of coercion, properly formulated scientific experimentation, and beneficence towards experiment participants

 1948, Universal Declaration of Human Rights: Universal Declaration of Human Rights (adopted by the General Assembly of the United Nations) expressed concern about rights of human beings being subjected to involuntary maltreatment.

1951 Henrietta Lacks: During treatment for cervical cancer, cells were taken from her tumor without her knowledge. Researcher George Otto Gey took these cells and noticed that, amazingly, the cells could be kept alive in culture. while the extraction of Henrietta’s cells, some 20 tons of cells have been grown from the HeLa line and were used to test the first polio vaccine in the 1950’s and have since been used for AIDS and cancer research.

1960’s Harvard Psilocybin Experiments: Two of his professors,Timothy Leary and Richard Alpert gave the psychedelic drug psilocybin to students and prisoners as part of a hypothesis that the then-legal drug could alter behavior in dramatic and beneficial ways. Due to the controversy and an article published in Crimson in 1962 they were dismissed by the university.

1962 Kefauver-Harris Drug Amendment: It strengthened federal oversight of drug testing and included a requirement for informed consent.

1964 Declaration of Helsinki: Helsinki, the World Medical Association articulated general principles and specific guidelines on use of human subjects in medical research, known as the Helsinki Declaration.

1974 The National Research Act: . For the Tuskegee Syphilis Study, President Richard Nixon signed the National Research Act into law.The act requires that all research using human subjects be reviewed by an Institutional Review Board as another step to ensure protection of human subjects.

1974 FDA Bureau of Medical Devices and Diagnostic Products: In February 1974, the FDA created the Bureau of Medical Devices and Diagnostic Products, this led to Advancements in technology for the significant growth in the medical device field.

1976 Medical Device Amendments: President Gerald Ford signed this amendment into law in order to increase FDA’s authority over the production of medical devices.

1979 The Belmont Report: The Belmont Report explains the three unifying ethical principles to guide human research: Respect for persons, Beneficence,and Justice.

1981 FDA Regulations Title 21: In follow-up to the Belmont Report, FDA and the Department of Health and Human Services formally revised regulations for human subject protections by creating Title 21, which includes regulations for the Protection of Human Subjects (Part 50), Financial Disclosure (Part 54), IRBs (Part 56), Investigational New Drug Applications (Part 312), Investigational Device Exemptions (Part 812), and Electronic Records (Part 11).

1990 International Conference on Harmonization Guidelines: Many European nations creating plans for global harmonization of regulatory requirements to reduce duplicate, time-consuming, and expensive procedures needed to market products internationally, while maintaining safeguards on quality, safety, and efficacy. This need led to the creation of the ICH guidelines in April of 1990.

1990 The Safe Medical Devices Act: The Safe Medical Devices Act brought about requirements for hospitals and health professionals to report incidents to the FDA and manufacturers when devices cause serious injury or death.

1991 The Common Rule: Captured in the Code of Federal Regulations, Title 45, Part 46, the rule Consist of description related with  the types of research subject to regulation.

1993 MedWatch: MedWatch was launched by the FDA as a system designed to collect health professionals’ reports of adverse events involving medical products. When safety hazards are detected, the FDA issues medical product safety alerts or orders product recalls, withdrawals, or labelling changes to protect the public health.

1996 Health Insurance Portability and Accountability Act: This Act requires that patients must be informed about, how their protected health information will be stored and kept confidential when they participate in a research trial.

1996 National Bioethics Advisory Commission:This was  created to explore ethical issues in science and medicine and advise the President on bioethical issues. The commission examined topics including cloning, human stem cell research, and research involving human subjects

1996 The World Health Organization Guidelines for Good Clinical Practice: The guideline deal with the justifications for a trial and protocol; protection of subjects; responsibilities of investigators, sponsors and monitors; assurance of data integrity and product accountability; and roles of  regulatory authorities. http://cdn2.hubspot.net/hub/149400/file-410979295-pdf/docs/CRT_Timeline_download.pdf

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149409/

FDA approved Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

0

Dec. 02, 2019: Akari Therapeutics announced the design of a pivotal Phase III pediatric trial in HSCT-TMA following a FDA End-of-Phase II meeting.

Akari announced that in another hematological condition, the patients after  long-term Phase II PNH study are now became transfusion independent on long-term treatment with nomacopan, who were  transfusion dependent.

HSCT-TMA is an orphan hematological condition with an estimated mortality rate of more than 80% in children with the severe form of the disease and is  being targeted with nomacopan. The study will be in two parts, Part A with data from seven patients used to confirm dosing and endpoints for Part B, with the pharmacokinetic (PK) modelling approved with the FDA through Akari’s participation in the Model Informed Drug Discovery Program (MIDD). https://fda.einnews.com/pr_news/503778385/akari-therapeutics-announces-pivotal-phase-iii-trial-design-of-nomacopan-in-pediatric-hematopoietic-stem-cell-transplant-related-thrombotic

The U.S. Food and Drug Administration (FDA) approved Medical devices (pacemakers and defibrillators)That Help Keep the Heart Beating

0

Dec. 02, 2019: The U.S. Food and Drug Administration (FDA) approved Medical devices such as pacemakers and defibrillators that have extended and improved the lives of millions of people living with heart disease.

These medical devices used to treat cardiovascular disease, cardiovascular conditions, and other related issues. FDA-approved medical devices can be implanted in a person’s body and also used outside the body.

Some categories of FDA-approved devices are :Automated external defibrillators (AEDs) (Portable and automatic, help in cardiac arrest), Cardiac ablation catheters (cardiac ablation catheters treat abnormally rapid  heartbeats),Cardiovascular angioplasty devices (intended to improve blood flow to the heart, reduce chest pain, and treat heart attacks), Cardiac pacemakers (deliver electrical stimulation to make heart beat at a more appropriate rate)Implantable cardioverter defibrillators ( monitor heart rhythms and deliver shocks if dangerously fast rhythms are detected), Prosthetic (artificial) heart valves (Used for replacing diseased or dysfunctional heart valves) Stents( inserted permanently into an artery to help improve blood flow). https://fda.einnews.com/pr_news/503823266/fda-approved-devices-that-help-keep-the-heart-beating

Merck’s Ebola Vaccine (Ervebo) Approved in Europe by the European Commission

0

Dec. 03, 2019: Merck with its Researchers, healthcare providers and global health officials finally breathe a sigh of relief after the hardwork of two years ( 2014 and 2016 ).

The very first Ebola vaccine (Ervebo) was finally approved in Europe by the European Commission. This vaccine itself is actually a recombinant virus, based on the backbone of vesicular stomatitis virus originating from sheep and goats.

Because the immune system generates antibodies against the Ebola surface proteins, it creates protection against the Ebola virus itself.

Whittaker said,“This vaccine gives very quick, robust immunity, and the virus itself is relatively slow in transmitting, so the two things together will allow this ring vaccination protocol to actually work,” The approval of the vaccine in Europe is also a major step in establishing a stock of the vaccine by an alliance called Gavi.-it’s a global NGO that can act immediately whenever the need arises.”

https://cornellsun.com/2019/12/02/ebolas-expiration-mercks-ebola-vaccine-approved-in-europe/

Aquestive Therapeutic’s Libervan (diazepam) Buccal Film Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for the Management of Seizure Clusters

0

Dec. 02, 2019:  Aquestive Therapeutics, Inc. announced the completion, as planned, of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its therapeutic candidate Libervant™ (diazepam) Buccal Film designed for the management of seizure clusters.  Libervant has received orphan drug designation by FDA.

 Aquestive Therapeutics look forward to sharing the results from the single dose crossover study at the imminent American Epilepsy Society 2019 Annual Meeting. These results will confirm the dosing algorithm and satisfy the final clinical requirement as requested by the FDA.

Libervant has a potential to be the first oral therapy approved by the FDA for  managing seizure clusters in the population of 1.2 million refractory epilepsy patients and also the first diazepam based treatment method  and delivering a consistent predictable dose to almost all patients. https://fda.einnews.com/pr_news/503772367/aquestive-therapeutics-completes-rolling-submission-of-new-drug-application-nda-to-u-s-food-and-drug-administration-fda-for-libervant-diazepam

FDA approved Innovent Biologic’s Acceptance of NDA submission for Pemigatinib(FGFR1/2/3 inhibitor) in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

0

Dec 02, 2019:  Innovent Biologics, Inc. announced that Incyte submit the new drug application (NDA)  to the U.S. Food and Drug Administration (FDA) for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements has been accepted for Priority Review by FDA.  

In December 2018, collaboration between Innovent and Incyte established for three clinical-stage product candidates discovered and developed by Incyte, including pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). As per the terms of the agreement Innovent has received the rights to develop and commercialize the three resources in hematology and oncology in Mainland China, Hong Kong, Macau and Taiwan. sIn November 2019, IND approvals for all three assets were granted by the National Medical Products Administration (“NMPA”). Data collected from Incyte’s FIGHT-202 study evaluating pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma is responsible for NDA submission.

Data from these studies recently presented at the European Society for Medical Oncology (“ESMO”) 2019 Congress, demonstrated that in patients retain FGFR2 fusions or rearrangements (Cohort A), pemigatinib monotherapy resulted in an overall response rate (“ORR”) of 36 percent (primary endpoint), and median duration of response (“DOR”) of 7.5 months (secondary endpoint) with a median follow-up of 15 months. Adverse events were controllable and consistent with the mechanism of action of pemigatinib. Cholangiocarcinoma is a rare form of cancer of the bile duct. http://innoventbio.com/en/#/news/164

The European Commission approved Celltrion’s Remsima SC (infliximab) trials for the treatment of Chron’s disease, ulcerative colitis and rheumatoid arthritis

0

Nov 29, 2019: Evaluating a subcutaneous (SC) biosimilar version of the treatment in patients with Chron’s disease, ulcerative colitis and rheumatoid arthritis, Celltrion has revealed data from its Remsima SC (infliximab) trials.

The European Commission approved this drug  for patients with rheumatoid arthritis, marking it as the world’s first approved subcutaneous formulation of infliximab.

Patients with Remsima SC  shown to have a stable potency while patients with RA on Remsima SC develop fewer anti-drug antibodies – which leads to improve the effectiveness of a treatment – compared with those on CT-P13 IV.

On the 19th September of this year the European Medicines Agency’s (EMA) human medicines committee (CHMP) issued an optimistic opinion for the subcutaneous version of the drug, also known as CT-P13, as a line extension, and the data from that  trials was submitted to the EMA as part of the application.

Celltrion has also announced the submission a advance variation to the marketing authorisation of Remsima SC, to extend the indication in inflammatory bowel disease with the approval decision expected in mid-2020. https://www.celltrionhealthcare.com/en-us/board/newslist

EOS imaging receives U.S. FDA 510(k) clearance for EoSedge™ its new generation innovative imaging system , EoSedge in Europe, Canada and Australia

0

Nov 29, 2019 – EOS imaging announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new generation imaging system, EOSedge (Europe, Canada and Australia).

New system will be unveiled in Radiological Society of North America (RSNA) 2019 Annual Meeting which is going to be held on December 1st, in Chicago.EOSedge is the first general X-ray system motorized by a high-resolution photon counting detector, delivering optimal image quality for outstanding musculoskeletal imaging exams. Flex Dose™ technology by

EOSedge in order to modulate radiation dose along the patient’s body, as well as an open cabin with a motorized, enlarged patient platform to facilitate easy and comfortable access for a broad range of patients in order to deliver larger fields of examination.

EOSedge and the first-generation EOS system are designed to work flawlessly with the Advanced Orthopedic Solutions, that include 3DServices, EOSapps 3D surgical planning for spine, hip and knee as well as EOSlink™, which delivers the EOS surgical plan into the operating room to be used with advanced surgical technologies. https://www.eos-imaging.us/sites/default/files/press-release/PR_EOS%20imaging_FDA%20Clearance_29.11.19_EN_vf_0.pdf

Y-mAbs Initiates Submission of Biologics License Application to U.S. FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma

0

Nov. 29, 2019 : Y-mAbs Therapeutics, Inc., announced that it is the submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of its Biologics License Application (“BLA”) for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma under the FDA’s Rolling Review process.

In August 2018, naxitamab, which is an anti-GD2 monoclonal antibody, inward Breakthrough Therapy Designation by the FDA that facilitates frequent interactions with the FDA review team.

The Rolling Review process allows Y-mAbs to submit individual portions of the BLA for review, rather than waiting until all portions are completed and submitted to the FDA for review. Upon potential approval, the Company intends to commercialize naxitamab in the U.S. https://fda.einnews.com/pr_news/503569114/y-mabs-initiates-rolling-submission-of-biologics-license-application-to-u-s-fda-for-naxitamab-for-treatment-of-neuroblastoma

US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for AstraZeneca’s Imfinzi (durvalumab) for the treatment of patients with extensive-stage small cell lung cancer

0

Nov 29, 2019:US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for AstraZeneca’s Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).

SCLC is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly even with initial response to platinum-based chemotherapy.A Prescription Drug User Fee Act date is set for the first quarter of 2020.The sBLA was based on positive results from the Phase III CASPIAN trial published in The Lancet, showing Imfinzi in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) established a statistically considerable and clinically meaningful improvement in overall survival (OS) vs. SoC.

Death rate was reduced by 27% with median OS of 13.0 months for Imfinzi plus chemotherapy vs. 10.3 months for SoC. Result data showed an approximate of 33.9% of patients were alive at 18 months following treatment with Imfinzi plus chemotherapy vs. 24.7% of patients receiving SoC. https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer.html

Collaboration of Bayer and Pharmaron to develop new molecular entities for veterinary medicines

0

Nov 28, 2019:Bayer and Pharmaron jointly develop new molecular entities for veterinary medicines, this will include drug substance and drug product manufacturing to support Bayer’s research, development and commercialization needs.

The goal of Bayer and Pharmaron is to provide veterinarians, pet owners and farmers with modern therapies that address unmet medical needs of their animal patients.

Pharmaron will provide state-of-the-art CMC capabilities and resources to speed up the development of preclinical and clinical projects for Bayer Animal Health.

To offer a variety of future therapeutic options for diseases that still cannot be adequately treated today,they facilitate the exploration of the small molecule-based chemical space as small molecules have always been the backbone of innovative drugs in veterinary medicines. https://media.bayer.com/baynews/baynews.nsf/ID/4E1384544C3EEC21C12584BF0041B78C?OpenDocument

QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Plus Test the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms

0

Nov 27, 2019: QIAGEN and DiaSorin received FDA approval for the LIAISON QuantiFERON-TB Plus Test (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.

This test was developed by QIAGEN and DiaSorin in order to offer streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology.

QFT-Plus users are gaining admittance to the LIAISON’s powerful, highly elastic automation for all throughput segments, as well as to LIAISON’s broad list of more than 100 tests. This test was introduced in Europe in 2018 and is planned for China in 2020. https://corporate.qiagen.com/newsroom/press-releases/2019/20191127_diasorin_fda